Aprotinin (APT) NEW

Hangzhou Meiya Pharmaceutical Co., Ltd. which was founded in March of 2006, is mainly engaged in nucleotide series products, and it is a listed enterprise on the National Equities Exchange and Quotations(Stock Code: 833650). The predecessor of the company was Hangzhou Meiya Biotechnology Co., Ltd, which was founded in 1998. Through the whole progress, the company is always focusing on the development and production of preparation process, as well as process improvement. In November of 2012, Hangzhou Meiya set a wholly-owned company as its sales center: Shanghai Nucleosides Bio-Technology Co., Ltd. In January of 2014, Hangzhou Meiya set another wholly-owned company as its production site: Meiya Haian Pharmaceutical Co., Ltd., with a total investment exceeding 120 million RMB. Meiya has the Drug Production License and nearly 10,000 square meters of workshop of which meets GMP requirements. 　　Hangzhou Meiya, Shanghai Nucleosides Bio-Technology, and Meiya Haian Pharmaceutical all have their own import and export rights. Meiya produces more than 50 varieties, including nucleoside, nucleotide monophosphate, nucleotide diphosphate, nucleotide triphosphate, cyclic nucleotide, polynucleotide, yeast nucleotide, enzyme preparation, etc. Meiya is one of the top nucleotide manufacturers in China.